MedTrace Logo

Treatment of Prostate Cancer With Firmagon®

NCT01710098 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2020-04-13

No results posted yet for this study

Summary

How are testosterone levels of patients with prostate cancer under treatment with Firmagon® changing.

Former studies showed a quick fall of testosterone levels after start of therapy with Firmagon® and a quick recovery when therapy is stopped. The investigators want to prove this in a normal outpatient urologist setting. Furthermore data is collected to prove the adherence to the German S3-Guideline for the treatment of prostate cancer.

Conditions

Interventions

DRUG

Degarelix

subcutaneous injection

Sponsors & Collaborators

  • United Clinic Management GmbH

    lead INDUSTRY

Principal Investigators

  • Leopold Durner, MD · UCM GmbH

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-06-30
Completion
2015-09-24

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01710098 on ClinicalTrials.gov